Steven Kheloussi, PharmD, MBA, FAMCP

Panelists discuss how the economic toll of poor LDL-C control demands workplace and systemwide prevention strategies.

Panelists discuss how long-term LDL-C exposure heightens cardiovascular risk, making early and sustained lowering crucial.

Panelists discuss how improving adherence to LDL-lowering therapies is essential for sustained cardiovascular protection.

Panelists discuss how payer controls and prior authorization policies delay and derail LDL-lowering therapy.

Panelists discuss how PCSK9 inhibitors remain underused due to access, cost, and adherence barriers.

Panelists discuss how nonstatin agents are chosen and when combination therapy should be introduced for high-risk patients.

Panelists discuss how global LDL thresholds below 55 mg/dL influence care and challenge U.S. practice to evolve.

Panelists discuss how reinstating LDL-C targets in quality programs could improve outcomes and accountability.

Panelists discuss how substituting LDL outcomes with statin-use metrics weakened cholesterol management quality.

Panelists discuss how removing LDL-C targets in 2013 shifted focus from outcomes to statin use, weakening control efforts.

Panelists discuss how social determinants such as access, income, and literacy drive disparities in LDL-C control.

Panelists discuss how real-world programs like PROMPT-LIPID expose undertreatment patterns and guide care improvement.

Panelists discuss how pharmacy-related delays and limited escalation practices widen LDL-C management gaps.

Panelists discuss how: clinical inertia, patient apathy, and the asymptomatic nature of high cholesterol all contribute to undertreatment and poor outcomes.

Panelists discuss how: LDL-C control remains a national crisis, with many patients not on therapy or failing to reach target levels despite the availability of effective treatments.